Botswana Vaccine Institute Partners with Techinvention for Cutting-Edge Veterinary Vaccine Manufacturing Facility The Botswana Vaccine Institute (BVI) has made a significant investment in the modernization of its veterinary vaccine production capabilities by partnering with Techinvention, a global leader in biopharmaceutical engineering and technology. This partnership will result in the creation of a state-of-the-art vaccine manufacturing facility, expanding BVI’s ability to produce high-quality vaccines for animal health. The new facility, located at BVI’s headquarters in Gaborone, will utilize advanced technologies and automation to enhance vaccine production efficiency and reliability. Techinvention will design and construct the facility using the latest manufacturing processes and quality control systems to ensure the production of safe and effective vaccines. “This partnership with Techinvention is a transformative moment for BVI and the veterinary vaccine industry in Africa,” said Dr. Johannes Ndunguru, Director of BVI. “We recognize the critical role of animal health in ensuring food security and protecting livelihoods across the continent. This new facility will enable us to increase our production capacity, reduce lead times, and deliver innovative vaccines to protect livestock from devastating diseases.” Techinvention brings a wealth of expertise in biopharmaceutical facility design and construction, having delivered numerous projects for leading vaccine manufacturers worldwide. “We are delighted to collaborate with BVI on this important initiative,” said Dr. Peter Wilce, CEO of Techinvention. “Our experience in creating high-performance vaccine manufacturing facilities will ensure that BVI has the infrastructure it needs to address the growing demand for veterinary vaccines in Africa and beyond.” The new facility is expected to be operational by 2025 and will produce a range of veterinary vaccines, including those against foot-and-mouth disease, bovine tuberculosis, and African swine fever. It will also serve as a platform for research and development, enabling BVI to explore new vaccine technologies and address emerging animal health challenges. “The establishment of this new facility underscores Botswana’s commitment to innovation and the advancement of animal health,” said Dr. Edwin Dikoloti, Minister of Agriculture and Food Security. “We believe that this investment will not only benefit Botswana but also contribute to the broader fight against animal diseases in Africa and globally.” The partnership between BVI and Techinvention is a testament to the growing importance of veterinary vaccine production in Africa. By harnessing the latest technologies and expertise, this collaboration will enhance the continent’s ability to prevent and control animal diseases, safeguard livestock, and promote food security for future generations.Techinvention Lifecare to Oversee Vaccine Plant Installation in BotswanaTechinvention Lifecare to Oversee Vaccine Plant Installation in Botswana Techinvention Lifecare, a Mumbai-based startup, has been selected by the Botswana Vaccine Institute (BVI) as a consultant to oversee the installation of a new state-of-the-art vaccine manufacturing unit in Gaborone, Botswana. The project involves the construction of a new mixing and filling block for veterinary vaccines that meets current Good Manufacturing Practices (cGMP) and other global standards. This will allow BVI to increase its production capacity, improve product quality and efficacy, and comply with regulatory requirements. The project, which began in 2022, is expected to be operational by 2026. Techinvention Lifecare will provide comprehensive project management support, ensuring timely completion and adherence to all relevant protocols. BVI, which has been a key player in the production and distribution of veterinary vaccines since the 1970s, will use the new facility to meet growing demand in the region and explore new markets.Botswana Vaccine Institute (BVI) has partnered with Techinvention, a leading biotechnology engineering firm, to establish a state-of-the-art veterinary vaccine manufacturing facility in Botswana. This collaboration aims to enhance the country’s vaccine production capabilities and foster self-sufficiency in veterinary health. The new facility will leverage Techinvention’s expertise in vaccine manufacturing technology and BVI’s knowledge of the local veterinary vaccine market. It will focus on developing and producing high-quality vaccines for livestock diseases prevalent in Botswana and the Southern African region. By establishing this facility, BVI aims to reduce the reliance on imported vaccines, ensuring a reliable and timely supply of vaccines for farmers and livestock owners. The facility will also serve as a training hub for local scientists and technicians, building capacity in veterinary vaccine production in Botswana. Techinvention’s President, Dr. Mark Anderson, expressed enthusiasm about the partnership, stating, “We are honored to collaborate with BVI on this important project. Our expertise in vaccine manufacturing technology will complement BVI’s local knowledge, creating a synergistic partnership that will benefit the veterinary industry in Botswana and beyond.” Dr. Moses Moshabela, CEO of BVI, emphasized the significance of the project, saying, “This partnership with Techinvention marks a major milestone for Botswana. The establishment of a local veterinary vaccine manufacturing facility will not only enhance our vaccine production capabilities but also foster innovation and create employment opportunities in the biotechnology sector.” The new facility is expected to be operational by 2025 and will contribute to the development of Botswana’s biotechnology industry, supporting the country’s economic diversification efforts.